# Skye Bioscience, Inc. (SKYE)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/SKYE/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 0 | $ -23.30M | $ -15.68M | $ 35.7K | $ -497.3K |
| 2025 | $ 0 | $ -57.26M | $ -9.45B | $ 273.6K | $ 20.02M |
| 2024 | $ 0 | $ -27.92M | $ -28.21M | $ 455.6K | $ 68.15M |
| 2023 | $ 0 | $ -40.70M | $ -15.10M | $ 4.62M | $ -2.13M |
| 2022 | $ 0 | $ -21.76M | $ -14.27M | $ 1.98M | $ -3.01M |
| 2021 | $ 0 | $ -10.13M | $ -7.80M | $ 2.14M | $ 5.86M |
| 2020 | $ 0 | $ -8.36M | $ -7.72M | $ 1.50M | $ 450.8K |
| 2019 | $ 0 | $ 1.36M | $ -7.78M | $ 387.1K | $ 548.1K |
| 2018 | $ 0 | $ -25.35M | $ -5.21M | $ 1.36M | $ -15.56M |
| 2017 | $ 0 | $ -4.17M | $ -4.47M | $ 235.0K | $ -800.1K |
| 2016 | $ 0 | $ -4.37M | $ -4.90M | N/A | $ -1.45M |
| 2015 | $ 0 | $ -6.80M | $ -5.24M | N/A | $ 471.0K |
| 2014 | $ 10.8K | $ -3.63M | $ -1.23M | N/A | $ -453.5K |
| 2013 | $ 489.4K | $ -271 | $ -13.3K | $ 41.0K | $ 87.0K |
| 2012 | $ 104.4K | $ 6.4K | $ -83.1K | $ 0 | $ 38.6K |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | -0.07 |
| Liabilities / Eq | -23.19 |
| Current Ratio | 0.95 |

## Other views

- [Metrics](https://sponda.capital/en/SKYE.md)
- [Charts](https://sponda.capital/en/SKYE/charts.md)
- [Compare](https://sponda.capital/en/SKYE/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-29.